Quantum-Si Signs Lease for Product Development and Operations Facility in San Diego Biotechnology Hub
June 24 2021 - 4:05PM
Business Wire
Quantum-Si Incorporated, a company pioneering next-generation
semiconductor chip-based proteomics, announced today that it has
entered into a lease agreement with Phase 3 Real Estate Partners,
Inc. to develop a 25,586-square-foot product development and
operations facility in San Diego, CA.
The new facility, located in Sorrento Mesa, is being designed to
scale production and expand research and development efforts. We
expect this site will play a vital role in expanding the company’s
recruitment efforts within our product development team as the
company prepares for commercial readiness. The location was
specifically selected due to its vast network of talent to support
research and development activities and to partner with local
experts who can contribute to transforming proteomics to make a
significant impact on drug discovery, academic research and
diagnostics. Operations are expected to begin in Q3 2021.
“As we continue our efforts to commercialize single-molecule
protein sequencing to disrupt and expand an estimated $36 billion
proteomics market primed for significant growth, we are developing
a benchtop platform designed to be scaled to streamline the
increased need for resolution and sensitivity,” said John Stark,
Chief Executive Officer of Quantum-Si. “In an effort to accelerate
our efforts, we believe this facility will help us scale necessary
infrastructure that will foster collaboration across our research
and development teams and advance production capacity as we recruit
high-caliber talent focused on moving proteomics in the digital
era.”
About Quantum-Si
Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused
on revolutionizing the growing field of proteomics. The company’s
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable single-molecule
next-generation protein sequencing, and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of Quantum-Si Incorporated (the “Company”) may differ from
its expectations, estimates, and projections and, consequently, you
should not rely on these forward-looking statements as predictions
of future events. Words such as “expect,” “estimate,” “project,”
“budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,”
“will,” “could,” “should,” “believes,” “predicts,” “potential,”
“continue,” and similar expressions (or the negative versions of
such words or expressions) are intended to identify such
forward-looking statements. These forward-looking statements
include, without limitation, the Company’s expectations with
respect to future performance, development of products and
services, potential regulatory approvals, the timing for commencing
operations at the new facility, the potential impact of the new
facility on our business, and the size and potential growth of
current or future markets for the Company’s future products and
services. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from those discussed in the forward-looking
statements. Most of these factors are outside the Company’s control
and are difficult to predict. Factors that may cause such
differences include, but are not limited to: the impact of COVID-19
on the Company’s business; the inability to maintain the listing of
the Company’s shares of Class A common stock on The Nasdaq Stock
Market following its recently-completed business combination; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; changes in
applicable laws or regulations; the ability of the Company to raise
financing in the future; the success, cost and timing of the
Company’s product development activities; the potential attributes
and benefits of the Company’s products and services; the Company’s
ability to obtain and maintain regulatory approval for its
products, and any related restrictions and limitations of any
approved product; the Company’s ability to identify, in-license or
acquire additional technology; the Company’s ability to maintain
its existing lease, license, manufacture and supply agreements,
including the lease for the new facility; the Company’s ability to
compete with other companies currently marketing or engaged in the
development of products and services that the Company is
developing; the size and growth potential of the markets for the
Company’s future products and services, and its ability to serve
those markets, either alone or in partnership with others; the
pricing of the Company’s products and services following
anticipated commercial launch; the Company’s estimates regarding
future expenses, future revenue, capital requirements and needs for
additional financing; the Company’s financial performance; and
other risks and uncertainties indicated from time to time in the
proxy statement/prospectus relating to the business combination,
including those under “Risk Factors” therein, and in the Company’s
other filings with the SEC. The Company cautions that the foregoing
list of factors is not exclusive. The Company cautions readers not
to place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210624005960/en/
Investor Relations Mike Cavanaugh or Mark Klausner
Westwicke, an ICR Company (646) 677-1838 QSI-IR@westwicke.com
Media Relations Cammy Duong Westwicke, an ICR Company (203)
682-8380 QSI-PR@westwicke.com
Quality Systems (NASDAQ:QSII)
Historical Stock Chart
From Oct 2024 to Nov 2024
Quality Systems (NASDAQ:QSII)
Historical Stock Chart
From Nov 2023 to Nov 2024